ThromboGenics creates new company around pediatric brain tumor candidate
This article was originally published in Scrip
Executive Summary
Following up on a decision first mentioned in an August 2014 business update, ThromboGenics has spun out a new company called Oncurious to develop the early clinical-stage oncology candidate TB-403. VIB, a Belgian life sciences institute, is also a partner in the new venture, and it is hoped that access to basic research at VIB will allow Oncurious to go on to build an oncology pipeline behind TB-403. ThromboGenics will be the majority shareholder.
You may also be interested in...
Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.